Opioids for Pain Treatment in Persons with Opioid Use Disorder
Once you register for the course, you will have 30 days from the date of enrollment to complete the course. The exact date that your access expires will be indicated within the Course Summary box on this webpage.
Primary care physicians, nurses, mental health professionals, substance use disorder professionals, or any clinic staff who support behavioral health services.
This presentation will review safe and effective pain treatment, how to support recovery from opioid use disorder (OUD) and avoid relapse in patients with OUD, and how to avoid personal and public health consequences of opioid use disorder. Participants will be introduced to the general principles of effective pain treatment in patients with OUD, how to treat pain safely and effectively, how to address pain facilitators and opioid use disorder, and when to say ‘no’ to a request for long-term opioid therapy. Dr. Weimer will also discuss other options for treatment of pain.
- Identify principles of pain treatment in opioid use disorder.
- Describe pain treatment in opioid use disorder and chronic non-terminal, non-cancer pain.
Recording date: January 8, 2021
Date of original release: January 16, 2021
Most recent review/update: January 16, 2021
Termination date: January 15, 2024
Melissa Weimer, DO, MCR, FASAM
Assistant Professor; Medical Director of the Addiction Medicine Consult Service, Program in Addiction Medicine, Yale School of Medicine
Associate Program Director of the Addiction Medicine Fellowship Program, Medicine, Yale School of Medicine
Dr. Weimer is board certified in Internal Medicine and Addiction Medicine and has a clinical and research focus on expanding access to substance use disorders treatment, particularly in the hospital setting. She also has fellowship training and years of experience in the management of complex pain, particularly for patients with concomitant opioid use disorders. She is the Medical Director of the Yale Addiction Medicine Consult Service (YAMCS), a multidisciplinary, hospital based program to address the substance use disorder needs of patients admitted to Yale New Haven Hospital.
Dr. Weimer has worked tirelessly on a local, state and national level to improve access to evidence based treatments for patients with substance use disorder. Her work to expand addiction treatment in hospital settings started at Oregon Health & Science University where she worked with colleagues and community partners to create one of the nation's first hospital-based models to initiate addiction treatment while patients are hospitalized from a complication of their substance use. An experienced educator, she teaches health care students and professionals about substance use disorders and their treatment to promote the expansion of the addiction medicine workforce. She additionally serves as the Associate Program Director of the Yale Addiction Medicine Fellowship program.
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University (DMU) and the Iowa Primary Care Association. DMU is accredited by IMS to provide continuing medical education for physicians. DMU designates this enduring materials activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this activity for a maximum of 0.75 AOA Category 1-B credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- Other Healthcare Professionals: This live activity is designated for a maximum of 0.75 AMA PRA Category 1 Credit(s)™.
No ineligible company provided financial support for this continuing education activity.
The planning committee member(s) and speaker(s) will disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director.
Relevant to the content of this educational activity, the following individuals have no financial conflicts with ineligible companies to disclose:
- Julie Baker, MPA, CHCEF, Planning Committee Member
- Bery Engebretsen, MD, Planning Committee Member
- Nicolas Foss, MS, IADC, BACC, ICGC-II, Planning Committee Member
- Gagandeep Lamba, MA, MS, MBA, Activity Director/Coordinator, Planning Committee Member, and Moderator
- Elizabeth Noble, Activity Coordinator and Moderator
- Danielle O'Brien-Day, LMHC, CRC, Planning Committee Member
- Nicole Gastala, MD, Planning Committee Member and Speaker
- Andrea Storjohann, MSN, ARNP, PMHNP-BC, CADC, Planning Committee Member
- Carrie Schmidt, RN, Case Presenter
- Dawn Davies, ARNP, PMHNP-BC, AFN, Case Presenter
Relevant to the content of this educational activity, the following individual(s) have a conflict(s) with ineligible companies to disclose:
- Janice Landy, MD, Planning Committee Member - Does not have a conflict with a commercial interest company; however, does intend to discuss off-label uses of commercial products.
- Melissa Weimer, DO, MCR, FASAM, Speaker - Consultant for Path CCM, Inc.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
- 0.75 AMA PRA Category 1 Credits™
- 0.75 AOA Category 1B
- 0.75 CE Contact Hour(s)